Including Medical Management in the Urologic Approach to Idiopathic Retroperitoneal Fibrosis

Urology. 2021 Jun:152:167-172. doi: 10.1016/j.urology.2021.03.002. Epub 2021 Mar 11.

Abstract

Objective: To characterize the timing and effectiveness of medical management in resolving stent-dependent ureteral compression secondary to idiopathic retroperitoneal fibrosis (RPF), the long-term relevant outcomes, and the side effects of treatment.

Methods: A retrospective review of RPF patients diagnosed from 2002-2018 was performed. Patients with hydronephrosis due to ureteral involvement that were managed with medication and with temporary stenting as needed, but without initial ureterolysis, were included. Patient demographics and RPF management details were obtained, including the following subsequent events: ureterolysis, nephrectomy, recurrent upper tract obstruction, and medication side effects.

Results: Fifty-two patients met inclusion criteria. Resolution of ureteral obstruction with medical management and temporary renal drainage as needed occurred in 36 (69%) patients with a median stent duration of 16 months, and median clinical and radiographic follow up of 4.2 and 3.3 years, respectively. Recurrent obstruction after a stent-free period occurred in 9 (18%) patients. Ureterolysis was performed in 8 (15%) patients at a median of 2.2 years for medication intolerance, lack of radiographic response to medication, or persisting pain. Potential medication side effects occurred in 6 (12%) patients.

Conclusions: Medical management supported successful resolution of ureteral obstruction in 69% of patients without the need for ureterolysis after temporary renal drainage using stents, with rare incidence of worsening renal dysfunction or medication side effect. To date, this is the largest reported series of systematically managed RPF patients with obstructive uropathy receiving initial medical therapy and serves to counsel patients and advise urologists and nephrologists of the expected course and advantages and disadvantages of medical versus surgical management.

MeSH terms

  • Adult
  • Combined Modality Therapy
  • Drainage / instrumentation
  • Female
  • Follow-Up Studies
  • Humans
  • Hydronephrosis / epidemiology
  • Hydronephrosis / etiology
  • Hydronephrosis / therapy*
  • Incidence
  • Male
  • Middle Aged
  • Recurrence
  • Retroperitoneal Fibrosis / complications*
  • Retroperitoneal Fibrosis / therapy
  • Retrospective Studies
  • Stents*
  • Treatment Outcome
  • Ureter / drug effects
  • Ureter / surgery
  • Ureteral Obstruction / epidemiology
  • Ureteral Obstruction / etiology
  • Ureteral Obstruction / therapy*
  • Urological Agents / administration & dosage*
  • Urological Agents / adverse effects

Substances

  • Urological Agents